400 participants
The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
- Study Type:
- OBSERVATIONAL
- Last Updated:
- 2026-07-27
- Start Date:
- 2026-07-31
- Completion:
- 2028-07-31
Conditions
- Hepatocellular Carcinoma (HCC)
Interventions
- DRUG
- PROCEDURE
No Results Yet